The outcomes of studies investigating pancreatic cancer demonstrated the antitumor effects of GLP-1 on gemcitabine-resistant pancreatic cancer cells, and suggest that GLP-1 agonists, via the modulation of the NK-kβ signaling pathway, enhance the therapeutic effect of gemcitabine [43]. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.